AUTHORS
Lu Yu, Na Xu2, Xiaoli Liu, MD3, Bingcheng Liu4, Li Zhou5, Jian Huang6, Yunfan Yang7, Huanling Zhu8, Qun He9, Jingnan Sun10, Hai Lin11, Danhui Fu12, Minghui Duan13, Xin Du, MD14, Yanli Zhang, MD15, Yu Zhu, MD16, Lisi Huang17, Xin Huang18, Jianyu Weng, MD19, Xiaoyi Lv20, Ling Song21, Chunyan Chen22, Qin Wen23, Fangbing Zhu24, Bing Chen25, Huibing Dang26, Sili Wang27, Limei Chen, MD28, Waiyi Zou29, Qian Jiang Jr, MD30
AFFILIATIONS
1 Peking University People's Hospital, Beijing, China
2 Nanfang Hospital, Southern Medical University, Guangzhou, China
3 Nanfang Hospital, Southern Medical University, Guangzhou, China
4 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
5 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
7 West China Hospital, Sichuan University, Chengdu, China
8 West China Hospital, Sichuan University, Chengdu, China
9 Xiangya Hospital of Central South University, Changsha, China
10 The First Hospital of Jilin University, Changchun, China
11 The First Hospital of Jilin University, Changchun, China
12 Fujian Medical University Union Hospital, Fuzhou, China
13 Peking Union Medical College Hospital, Beijing, China
14 Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
15 Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
16 Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
17 Guangdong Provincial People's Hospital, Guangzhou, China
18 Guangdong Provincial People's Hospital, Guangzhou, China
19 Guangdong Provincial People's Hospital, Guangzhou, China
20 The First Hospital of China Medical University, Shenyang, China
21 Xinyang Central Hospital, Xinyang, China
22 Qilu Hospital of Shandong University, Jinan, China
23 The Second Affiliated Hospital of Army Medical University, Chongqing, China
24 The First Affiliated Hospital of Bengbu Medical University, Bengbu, China
25 Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China
26 The First Affiliated Hospital of Nanyang Medical College, Nanyang, China
27 Zhongshan Hospital of Xiamen University, Xiamen, China
28 The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
29 The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
30 Peking University People's Hospital, Beijing, China
ABSTRACT
Background
Asciminib, an allosteric BCR::ABL1 inhibitor specifically targeting the ABL myristoyl pocket, was approved in China in May 2025 for adults with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP). Real-world data from China are limited. This multicenter study evaluated retrospectively the real-world outcome of asciminib as front-line or later-line therapy in the CML-CP patients.
Methods
This study included CML-CP patients diagnosed by WHO 2022 criteria receiving asciminib ≥3 months of follow-up at 73 centers in China, with data cutoff on July 28, 2026. Treatment efficacy and safety were collected from the medical records. Treatment responses were assessed according to the 2025 ELN milestone.
Results
The front-line cohort included 172 patients. Median age was 44 (IQR, 35-59) years. 111 (65%) patients were male. 91 (53%) patients had comorbidities. According to the ELTS score, 108 (63%) patients were classified as low risk, 38 (22%) as intermediate risk, and 26 (15%) as high risk. 162 (94%) patients initiated asciminib at 80 mg QD, and 10 (6%) initiated 40 mg QD. 172, 104 and 15 patients had ≥3, ≥6 and ≥12 months of follow-up period. With a median follow-up of 7 (IQR, 5-9) months,168 (98%) patients achieved a CHR by 3 months. 148 (86%), 72 (42%), and 19 (11%) patients achieved CCyR, MMR, and MR4.0 at 3 months; 101 (97%), 69 (66%), and 35 (34%) at 6 months; 15 (100%), 13 (87%), and 8 (53%) at 12 months. Unfavorable response occurred in 6 (3%) patients at a median of 7 (IQR, 3-9) months, and one progressed to blast crisis at 2 months. 5 of 7 patients had BCR::ABL1 mutations including A337T (n = 2), G463D (n = 1), A337T + A433D (n = 1), and F359V/C/I + T315I (n = 1), 2 had no detected mutation. The most common grade ≥3 hematologic AEs was thrombocytopenia 18 (11%), followed by neutropenia 7 (4%) and anemia 2 (1%). Common non-hematologic AEs included rash 16 (9%), arthralgia/myalgia 11 (6%), and gastrointestinal discomfort 8 (5%). Pancreatitis occurred in 1 (1%) patient. 3 (2%) patients discontinued asciminib due to AEs.
The later-line cohort included 99 patients with a median of 3 prior TKI failures due to TKI intolerance (n = 60, 61%) and resistance (n = 39, 39%). Median age was 52 (IQR, 41-63) years. 68 (69%) patients were male. 50 (51%) patients had comorbidities. 58 (59%) patients initiated asciminib at 80 mg QD, and 41 (41%) initiated 40 mg QD. 99, 57 and 15 patients had ≥3, ≥6 and ≥12 months of follow-up period. Among the evaluable patients, with a median follow-up of 8 (IQR, 5-11) months, 14/15 (93%) patients achieved a CHR by 3 months; 23/41 (56%), 23/61 (38%) and 16/78 (21%) patients achieved CCyR, MMR, and MR4 at 3 months; 16/25 (64%), 19/38 (50%) and 17/51 (33%) at 6 months; 3/4 (75%), 6/9 (70%) and 4/12 (39%) at 12 months. Unfavorable response occurred in 6 patients, 5 of whom had received ≥4 prior lines of therapy. 2 patients had BCR::ABL1 T315I and F359V + Y253H + T315I mutations, respectively. The most common grade ≥3 hematologic AEs was thrombocytopenia 11 (11%), followed by neutropenia 4 (4%) and anemia 4 (4%). Common non-hematologic AEs included rash 6 (6%), arthralgia/myalgia 3 (3%), and gastrointestinal discomfort 1 (1%). Grade ≥3 non-hematologic AEs included lipase elevation in 3 (3%) patients and triglyceride elevation in 1 (1%) patient. 2 (2%) patients discontinued asciminib due to AEs.
Conclusions
This study confirms the clinical efficacy and safety of asciminib as front-line or later-line therapy for CML-CP patients in the real-world. Longer follow-up is needed.
DISCLOSURES
Lu Yu: No relevant conflicts of interest to declare.